Ob/Gyn Medical News about Papillomavirus Vaccines Uterine Cervical Neoplasms Vaccination Mass Screening

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Annals of Internal Medicine, 10/20/09

Kim JJ et al. – This analysis assessed the cost–effectiveness of HPV vaccination for women aged 35 to 45 years. It found that vaccination ranged from $116 950 to $381 590 per quality–adjusted life–year gained across various assumptions about how clinicians would screen for cervical cancer and HPV infection in addition to vaccination. Given currently available information, the effectiveness of HPV vaccination for women older than 30 years who are screened seems to be small. Compared with current screening that uses sensitive HPV DNA testing, HPV vaccination is associated with less attractive cost–effectiveness ratios in this population than those for other, well–accepted interventions in the United States.

<< Previous
Can differences in IVF success rates between centres be explained...

Next >>
Comparison of mild stimulation and conventional stimulation in...